that in primary care monitoring would be done predominantly by a nurse (e.g. nurse-led anticoagulation clinics) rather than by GPs. This is in broad agreement with the clinical experts consulted by ScHARR for TA261 who suggested that a 25%/75% GP/nurse split would be a more accurate assessment[11]. The assumption that a greater proportion of INR monitoring visits are handled by nurses would be unfavourable to rivaroxaban (see Section 0 of this report).

Apart from the original index event the economic model accounts for resource usage associated with recurrent PEs, incident DVTs, bleeding, PTS and CTEPH. Treatment of severe PTS is assumed to require in the first year three vascular surgery outpatient appointments and thereafter two GP visits per year, based the HTA report of Goodacre and colleagues[44]. The other states are assigned unit costs based on their severity and assumed location of treatment and, in the case of the CTEPH state, a requirement for pulmonary endodartectomy (PEA). Based on Condliffe and colleagues (2008)[43] it is assumed that 68.4% of CTEPH patients require a PEA (Table 13).

Overall the MS provides a comprehensive discussion of resource use estimates relevant to the decision problem. The ERG finds that the estimates are generally reasonable. However in some cases the manufacturer's assumptions are in disagreement with those of the ERG clinical expert and previous expert opinion sought by ScHARR in TA261[11]. The direction of the disagreement is in these cases favourable to rivaroxaban. These are explored by the ERG in scenario analyses in Section 4.3.

4.2.7 Costs

The unit cost of rivaroxaban used by the economic model is £2.10 per 15 mg or 20 mg tablet as given in BNF64[3] (MS Table 50 page 188). The daily acquisition cost for patients treated with rivaroxaban is therefore £4.20 for the first 21 days (15 mg twice a day) and £2.10 thereafter (20mg once a day). The cost of treatment in the first quarter totals £235.20 and £191.63 in subsequent quarters. Costs for enoxaparin and warfarin are also taken from BNF64[3]. The daily cost of enoxaparin is £9.77 assuming treatment with the UK licensed dose and a mean body weight of 80 kg (MS Table 48 page 182).
[redacted] The daily cost of warfarin is £0.06 (MS Table 50 page 188).